“Devarsh Vakil of HDFC Securities holds a positive view on Sun Pharma, highlighting its strategy of deploying strong cash reserves for meaningful global growth. He notes that the market is increasingly rewarding companies that invest for growth, like Sun Pharma, over those primarily focused on balance sheet strengthening.”